NCT05695638 Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
| NCT ID | NCT05695638 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Morten Ladekarl |
| Condition | Solid Tumor, Unspecified, Adult |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2020-07-01 |
| Primary Completion | 2030-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2020-07-01 with a primary completion date of 2030-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region. Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.
Eligibility Criteria
Inclusion Criteria: * Incurable, progressing and/or life-threatening cancer * Expected residual survival of at least 3 months * No efficient remaining standard treatment options * Patient recruited from the Region of Northern Jutland, Denmark Exclusion Criteria: * WHO Performance Status \>2 * Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment
Contact & Investigator
Morten Ladekarl, MD, DMSCi
PRINCIPAL INVESTIGATOR
Department of Oncology, Aalborg University Hospital, Denmark
Frequently Asked Questions
Who can join the NCT05695638 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor, Unspecified, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05695638 currently recruiting?
Yes, NCT05695638 is actively recruiting participants. Contact the research team at morten.ladekarl@rn.dk for enrollment information.
Where is the NCT05695638 trial being conducted?
This trial is being conducted at Aalborg, Denmark.
Who is sponsoring the NCT05695638 clinical trial?
NCT05695638 is sponsored by Morten Ladekarl. The principal investigator is Morten Ladekarl, MD, DMSCi at Department of Oncology, Aalborg University Hospital, Denmark. The trial plans to enroll 3,000 participants.